![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SDC1 |
Gene summary for SDC1 |
![]() |
Gene information | Species | Human | Gene symbol | SDC1 | Gene ID | 6382 |
Gene name | syndecan 1 | |
Gene Alias | CD138 | |
Cytomap | 2p24.1 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P18827 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6382 | SDC1 | GSM4909281 | Human | Breast | IDC | 4.25e-12 | 4.54e-01 | 0.21 |
6382 | SDC1 | GSM4909282 | Human | Breast | IDC | 2.37e-02 | 3.09e-01 | -0.0288 |
6382 | SDC1 | GSM4909285 | Human | Breast | IDC | 3.23e-29 | 6.20e-01 | 0.21 |
6382 | SDC1 | GSM4909289 | Human | Breast | IDC | 6.00e-08 | 6.62e-01 | 0.1064 |
6382 | SDC1 | GSM4909290 | Human | Breast | IDC | 2.79e-11 | 3.70e-01 | 0.2096 |
6382 | SDC1 | GSM4909291 | Human | Breast | IDC | 6.71e-18 | 5.57e-01 | 0.1753 |
6382 | SDC1 | GSM4909296 | Human | Breast | IDC | 2.00e-02 | 2.84e-01 | 0.1524 |
6382 | SDC1 | GSM4909297 | Human | Breast | IDC | 8.87e-03 | 1.72e-01 | 0.1517 |
6382 | SDC1 | GSM4909302 | Human | Breast | IDC | 1.41e-12 | 4.25e-01 | 0.1545 |
6382 | SDC1 | GSM4909304 | Human | Breast | IDC | 2.63e-06 | 3.75e-01 | 0.1636 |
6382 | SDC1 | GSM4909305 | Human | Breast | IDC | 2.59e-04 | 2.69e-01 | 0.0436 |
6382 | SDC1 | GSM4909311 | Human | Breast | IDC | 1.40e-02 | 3.21e-03 | 0.1534 |
6382 | SDC1 | GSM4909313 | Human | Breast | IDC | 9.09e-03 | 2.45e-01 | 0.0391 |
6382 | SDC1 | GSM4909317 | Human | Breast | IDC | 6.63e-35 | 7.95e-01 | 0.1355 |
6382 | SDC1 | GSM4909319 | Human | Breast | IDC | 6.66e-06 | -5.13e-02 | 0.1563 |
6382 | SDC1 | brca2 | Human | Breast | Precancer | 3.80e-08 | 3.21e-01 | -0.024 |
6382 | SDC1 | M2 | Human | Breast | IDC | 1.40e-06 | 5.66e-01 | 0.21 |
6382 | SDC1 | DCIS2 | Human | Breast | DCIS | 2.09e-50 | 4.40e-01 | 0.0085 |
6382 | SDC1 | CA_HPV_1 | Human | Cervix | CC | 8.81e-06 | -2.40e-01 | 0.0264 |
6382 | SDC1 | CA_HPV_3 | Human | Cervix | CC | 3.11e-06 | 1.79e-01 | 0.0414 |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00069799 | Breast | Precancer | response to oxidative stress | 70/1080 | 446/18723 | 1.59e-14 | 4.26e-12 | 70 |
GO:00485459 | Breast | Precancer | response to steroid hormone | 53/1080 | 339/18723 | 3.07e-11 | 3.66e-09 | 53 |
GO:00003029 | Breast | Precancer | response to reactive oxygen species | 38/1080 | 222/18723 | 1.47e-09 | 1.23e-07 | 38 |
GO:00319608 | Breast | Precancer | response to corticosteroid | 30/1080 | 167/18723 | 2.50e-08 | 1.65e-06 | 30 |
GO:00425429 | Breast | Precancer | response to hydrogen peroxide | 26/1080 | 146/18723 | 2.52e-07 | 1.26e-05 | 26 |
GO:00513848 | Breast | Precancer | response to glucocorticoid | 26/1080 | 148/18723 | 3.32e-07 | 1.57e-05 | 26 |
GO:00100389 | Breast | Precancer | response to metal ion | 47/1080 | 373/18723 | 3.88e-07 | 1.79e-05 | 47 |
GO:00420609 | Breast | Precancer | wound healing | 48/1080 | 422/18723 | 5.48e-06 | 1.63e-04 | 48 |
GO:00096368 | Breast | Precancer | response to toxic substance | 31/1080 | 262/18723 | 1.18e-04 | 2.12e-03 | 31 |
GO:00486087 | Breast | Precancer | reproductive structure development | 43/1080 | 424/18723 | 2.36e-04 | 3.56e-03 | 43 |
GO:00614587 | Breast | Precancer | reproductive system development | 43/1080 | 427/18723 | 2.75e-04 | 4.00e-03 | 43 |
GO:19035434 | Breast | Precancer | positive regulation of exosomal secretion | 5/1080 | 15/18723 | 1.17e-03 | 1.26e-02 | 5 |
GO:19035416 | Breast | Precancer | regulation of exosomal secretion | 5/1080 | 17/18723 | 2.19e-03 | 2.06e-02 | 5 |
GO:00515925 | Breast | Precancer | response to calcium ion | 18/1080 | 149/18723 | 2.37e-03 | 2.19e-02 | 18 |
GO:00515919 | Breast | Precancer | response to cAMP | 13/1080 | 93/18723 | 2.57e-03 | 2.33e-02 | 13 |
GO:0046661 | Breast | Precancer | male sex differentiation | 19/1080 | 165/18723 | 3.14e-03 | 2.65e-02 | 19 |
GO:0008584 | Breast | Precancer | male gonad development | 17/1080 | 141/18723 | 3.15e-03 | 2.65e-02 | 17 |
GO:0046546 | Breast | Precancer | development of primary male sexual characteristics | 17/1080 | 142/18723 | 3.39e-03 | 2.84e-02 | 17 |
GO:00466839 | Breast | Precancer | response to organophosphorus | 16/1080 | 131/18723 | 3.60e-03 | 2.98e-02 | 16 |
GO:00020649 | Breast | Precancer | epithelial cell development | 23/1080 | 220/18723 | 4.28e-03 | 3.35e-02 | 23 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0541846 | Oral cavity | EOLP | Fluid shear stress and atherosclerosis | 41/1218 | 139/8465 | 2.95e-06 | 2.16e-05 | 1.28e-05 | 41 |
hsa0520543 | Oral cavity | EOLP | Proteoglycans in cancer | 53/1218 | 205/8465 | 9.07e-06 | 5.33e-05 | 3.14e-05 | 53 |
hsa0541856 | Oral cavity | EOLP | Fluid shear stress and atherosclerosis | 41/1218 | 139/8465 | 2.95e-06 | 2.16e-05 | 1.28e-05 | 41 |
hsa0520553 | Oral cavity | EOLP | Proteoglycans in cancer | 53/1218 | 205/8465 | 9.07e-06 | 5.33e-05 | 3.14e-05 | 53 |
hsa0520562 | Oral cavity | NEOLP | Proteoglycans in cancer | 56/1112 | 205/8465 | 3.49e-08 | 5.85e-07 | 3.68e-07 | 56 |
hsa0541863 | Oral cavity | NEOLP | Fluid shear stress and atherosclerosis | 40/1112 | 139/8465 | 7.44e-07 | 9.10e-06 | 5.72e-06 | 40 |
hsa045126 | Oral cavity | NEOLP | ECM-receptor interaction | 24/1112 | 89/8465 | 3.56e-04 | 2.18e-03 | 1.37e-03 | 24 |
hsa0520572 | Oral cavity | NEOLP | Proteoglycans in cancer | 56/1112 | 205/8465 | 3.49e-08 | 5.85e-07 | 3.68e-07 | 56 |
hsa0541873 | Oral cavity | NEOLP | Fluid shear stress and atherosclerosis | 40/1112 | 139/8465 | 7.44e-07 | 9.10e-06 | 5.72e-06 | 40 |
hsa0451213 | Oral cavity | NEOLP | ECM-receptor interaction | 24/1112 | 89/8465 | 3.56e-04 | 2.18e-03 | 1.37e-03 | 24 |
hsa0541828 | Prostate | BPH | Fluid shear stress and atherosclerosis | 58/1718 | 139/8465 | 5.48e-09 | 7.24e-08 | 4.48e-08 | 58 |
hsa0520520 | Prostate | BPH | Proteoglycans in cancer | 72/1718 | 205/8465 | 4.16e-07 | 4.10e-06 | 2.54e-06 | 72 |
hsa045125 | Prostate | BPH | ECM-receptor interaction | 28/1718 | 89/8465 | 8.33e-03 | 2.64e-02 | 1.64e-02 | 28 |
hsa05418113 | Prostate | BPH | Fluid shear stress and atherosclerosis | 58/1718 | 139/8465 | 5.48e-09 | 7.24e-08 | 4.48e-08 | 58 |
hsa05205110 | Prostate | BPH | Proteoglycans in cancer | 72/1718 | 205/8465 | 4.16e-07 | 4.10e-06 | 2.54e-06 | 72 |
hsa0451212 | Prostate | BPH | ECM-receptor interaction | 28/1718 | 89/8465 | 8.33e-03 | 2.64e-02 | 1.64e-02 | 28 |
hsa0541829 | Prostate | Tumor | Fluid shear stress and atherosclerosis | 58/1791 | 139/8465 | 2.70e-08 | 3.44e-07 | 2.13e-07 | 58 |
hsa0520525 | Prostate | Tumor | Proteoglycans in cancer | 73/1791 | 205/8465 | 1.01e-06 | 9.82e-06 | 6.09e-06 | 73 |
hsa0541837 | Prostate | Tumor | Fluid shear stress and atherosclerosis | 58/1791 | 139/8465 | 2.70e-08 | 3.44e-07 | 2.13e-07 | 58 |
hsa0520535 | Prostate | Tumor | Proteoglycans in cancer | 73/1791 | 205/8465 | 1.01e-06 | 9.82e-06 | 6.09e-06 | 73 |
Page: 1 2 3 4 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
COL1A1 | SDC1 | COL1A1_SDC1 | COLLAGEN | Breast | DCIS |
COL1A2 | SDC1 | COL1A2_SDC1 | COLLAGEN | Breast | DCIS |
COL4A1 | SDC1 | COL4A1_SDC1 | COLLAGEN | Breast | DCIS |
COL4A2 | SDC1 | COL4A2_SDC1 | COLLAGEN | Breast | DCIS |
COL6A1 | SDC1 | COL6A1_SDC1 | COLLAGEN | Breast | DCIS |
COL6A2 | SDC1 | COL6A2_SDC1 | COLLAGEN | Breast | DCIS |
COL6A3 | SDC1 | COL6A3_SDC1 | COLLAGEN | Breast | DCIS |
MDK | SDC1 | MDK_SDC1 | MK | Breast | DCIS |
FN1 | SDC1 | FN1_SDC1 | FN1 | Breast | DCIS |
PTN | SDC1 | PTN_SDC1 | PTN | Breast | DCIS |
THBS1 | SDC1 | THBS1_SDC1 | THBS | Breast | DCIS |
THBS2 | SDC1 | THBS2_SDC1 | THBS | Breast | DCIS |
THBS3 | SDC1 | THBS3_SDC1 | THBS | Breast | DCIS |
ANGPTL4 | SDC1 | ANGPTL4_SDC1 | ANGPTL | Breast | DCIS |
TNC | SDC1 | TNC_SDC1 | TENASCIN | Breast | DCIS |
TNXB | SDC1 | TNXB_SDC1 | TENASCIN | Breast | DCIS |
COL1A1 | SDC1 | COL1A1_SDC1 | COLLAGEN | Breast | Healthy |
COL1A2 | SDC1 | COL1A2_SDC1 | COLLAGEN | Breast | Healthy |
COL4A1 | SDC1 | COL4A1_SDC1 | COLLAGEN | Breast | Healthy |
COL4A2 | SDC1 | COL4A2_SDC1 | COLLAGEN | Breast | Healthy |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SDC1 | deletion | Frame_Shift_Del | novel | c.644_647delNNNN | p.Thr215ArgfsTer7 | p.T215Rfs*7 | P18827 | protein_coding | TCGA-BH-A0H7-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD | ||
SDC1 | SNV | Missense_Mutation | c.491N>G | p.Thr164Ser | p.T164S | P18827 | protein_coding | tolerated(0.39) | possibly_damaging(0.724) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | |
SDC1 | SNV | Missense_Mutation | novel | c.703N>C | p.Val235Leu | p.V235L | P18827 | protein_coding | tolerated(0.15) | benign(0.05) | TCGA-ZJ-AAXB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
SDC1 | SNV | Missense_Mutation | rs753254745 | c.847N>A | p.Glu283Lys | p.E283K | P18827 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
SDC1 | SNV | Missense_Mutation | c.627N>T | p.Gln209His | p.Q209H | P18827 | protein_coding | tolerated(0.05) | possibly_damaging(0.756) | TCGA-AZ-4615-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | xeloda | PD | |
SDC1 | SNV | Missense_Mutation | novel | c.103N>A | p.Asp35Asn | p.D35N | P18827 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
SDC1 | SNV | Missense_Mutation | novel | c.132N>A | p.Phe44Leu | p.F44L | P18827 | protein_coding | deleterious(0) | possibly_damaging(0.856) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
SDC1 | SNV | Missense_Mutation | novel | c.187T>A | p.Ser63Thr | p.S63T | P18827 | protein_coding | tolerated(0.3) | benign(0.187) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SDC1 | SNV | Missense_Mutation | novel | c.97G>T | p.Asp33Tyr | p.D33Y | P18827 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
SDC1 | SNV | Missense_Mutation | rs747228317 | c.718N>G | p.Thr240Ala | p.T240A | P18827 | protein_coding | tolerated(0.76) | benign(0.046) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6382 | SDC1 | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | CAR138 T Cells | |||
6382 | SDC1 | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | CART-138 cells | |||
6382 | SDC1 | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | CD138 CAR T cells | |||
6382 | SDC1 | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | BT-062 | INDATUXIMAB RAVTANSINE | ||
6382 | SDC1 | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | HEPARIN | HEPARIN | 11333985 | |
6382 | SDC1 | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | CAR-T cells targeting CD138 |
Page: 1 |